Lung Therapeutics Joins the Austin Technology Incubator

tN_87266_25th anniv logoLung Therapeutics announced Wednesday it has joined the the Austin Technology Incubator, part of the IC2 Institute at the University of Texas at Austin.
Lung Therapeutics joins ATI’s Bio/Health Sciences Portfolio.
“Lung Therapeutics Inc.’s lead drug candidate, LT1-01, will allow for effective fluid drainage of the lung cavity, a rare consequence of hospitalized pneumonia, without the need for surgery,” according to a news release. “The company has been awarded more than $12 million in NIH funding toward the development and IND-enabling studies of the lead candidate, as well as a seed investment from the UT Horizon Fund, a strategic venture fund of the University of Texas System.”
“Lung Therapeutics is unique as a pharmaceutical startup. The team has a wealth of experience in the respiratory disease field and the company has removed much of the technology risk by funding advanced translational research and manufacturing with substantial federal dollars. We are very pleased to admit them into the ATI portfolio,” Cindy WalkerPeach, PhD, Director, Bio/Health Sciences Portfolio at ATI, said in a news release.


  1. I blog often and I seriously thank you for your content.
    This great article has truly peaked my interest. I’m going to take a
    note of your website and keep checking for new information about once per
    week. I opted in for your Feed as well.

  2. I’m not that much of a internet reade tto be honest but
    your sites really nice, keep it up! I’ll ggo ahead and bookmark your site too
    come back down the road. Cheers

Speak Your Mind